Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314353 · ClinicalTrials.gov registry record · Phase 2
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
A Phase 2 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00314353 is a Phase 2 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 7 participants.
The verdict
NCT00314353, a Phase 2 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.
Interventions
- DRUG Bevacizumab
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314353
The ClinicalTrials.gov registry entry for NCT00314353 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00314353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314353 about?
NCT00314353 is a clinical study titled "Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon". Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the c...
What is the current status of trial NCT00314353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2006-03. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00314353?
The interventions under investigation include: Bevacizumab (DRUG), Capecitabine (DRUG), Oxaliplatin (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00314353?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.